Andía Melero Víctor Manuel, Martín de Santa-Olalla Llanes María, Sambo Salas Marcel, Percovich Hualpa Juan Carlos, Motilla de la Cámara Marta, Collado Yurrita Luis
Servicio de Endocrinología y Nutrición, Hospital General Universitario Gregorio Marañón, Madrid, España.
Servicio de Endocrinología y Nutrición, Hospital General Universitario Gregorio Marañón, Madrid, España.
Endocrinol Nutr. 2015 Apr;62(4):152-60. doi: 10.1016/j.endonu.2014.12.009. Epub 2015 Mar 3.
Differentiated thyroid carcinoma staging is increasingly important due to the current trends to a less intensive therapy in low-risk patients. The TNM system is most widely used, but other systems based on follow-up of several patient cohorts have been developed. When these systems have been applied to other populations, results have been discordant. Our study evaluates the suitability of several differentiated thyroid carcinoma staging systems in a Spanish population.
729 patients with differentiated thyroid carcinoma and staging data available were enrolled. Mean follow-up time was 10.8 years. The TNM, EORTC, AMES, Clinical class, MACIS, Ohio, NTCTCS, and Spanish systems were applied to all histological types. The Kaplan-Meier survival curves for each system were analyzed, and compared using the proportion of explained variation (PEV).
The demographic and clinical characteristics of our population were similar to those of other Spanish and international cohorts reported. The best systems were NTCTCS, with 74.7% PEV, and TNM (68.3%), followed by the Ohio, MACIS, EORTC, and AMES systems with minimal differences between them, while the least adequate were the Spanish (55.2%) and Clinical class (47.1%) systems.
The NTCTCS staging system was found to be better than TNM in our population but, because of its simplicity and greater dissemination, the TNM appears to be recommended for staging of patients with differentiated thyroid carcinoma.
鉴于目前对低风险患者采用强度较低治疗的趋势,分化型甲状腺癌的分期变得愈发重要。TNM系统应用最为广泛,但基于多个患者队列随访情况的其他系统也已开发出来。当这些系统应用于其他人群时,结果并不一致。我们的研究评估了几种分化型甲状腺癌分期系统在西班牙人群中的适用性。
纳入729例有分化型甲状腺癌分期数据的患者。平均随访时间为10.8年。将TNM、欧洲癌症研究与治疗组织(EORTC)、AMES、临床分类、MACIS、俄亥俄、NTCTCS和西班牙系统应用于所有组织学类型。分析每个系统的Kaplan-Meier生存曲线,并使用解释变异比例(PEV)进行比较。
我们人群的人口统计学和临床特征与其他报道的西班牙及国际队列相似。最佳系统是NTCTCS,PEV为74.7%,其次是TNM(68.3%),随后是俄亥俄、MACIS、EORTC和AMES系统,它们之间差异极小,而最不合适的是西班牙系统(55.2%)和临床分类系统(47.1%)。
在我们的人群中,发现NTCTCS分期系统优于TNM,但由于TNM简单且应用更广泛,对于分化型甲状腺癌患者的分期,似乎推荐使用TNM。